MARVELON

This brand name is authorized in Austria, Canada, Ecuador, Estonia, Hong Kong SAR China, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, UK.

Active ingredients

The drug MARVELON contains a combination of these active pharmaceutical ingredients (APIs):

1	Desogestrel UNII 81K9V7M3A3 - DESOGESTREL
	Desogestrel is a progestogen. Like other progestogen-only pills, desogestrel is best suited for use during breast feeding and for women who may not or do not want to use oestrogens. In contrast to traditional progestogen-only pills, the contraceptive effect of desogestrel is achieved primarily by inhibition of ovulation. Other effects include increased viscosity of the cervical mucus.
	Read more about Desogestrel
2	17 alpha-Ethinylestradiol UNII 423D2T571U - ETHINYL ESTRADIOL
	Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.
	Read more about 17 alpha-Ethinylestradiol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MARVELON Tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03AA09	Desogestrel and ethinylestradiol	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations
Discover more medicines within G03AA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02042479, 02042487
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.160-05-03
EE	Ravimiamet	1062852, 1062863
GB	Medicines & Healthcare Products Regulatory Agency	175695, 185917, 26205
HK	Department of Health Drug Office	28591
JP	医薬品医療機器総合機構	254910CF1025, 254910CF2021
LT	Valstybinė vaistų kontrolės tarnyba	1010380, 1014664, 1065683, 1082481, 1084742
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	298M87
NL	Z-Index G-Standaard, PRK	39578
PL	Rejestru Produktów Leczniczych	100040953, 100127281, 100257517, 100269704, 100289859, 100335217, 100343955, 100346238, 100347060, 100347309, 100388892, 100423217, 100429734, 100443763
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68117001, W68117002